LEXEO THERAPEUTICS INC (LXEO) — insider trading
Health Care · NASDAQ
LEXEO THERAPEUTICS INC (LXEO) has 28 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 28 (latest 2026-09-24).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Tamayo Louis Edward | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 54,750 | — | $0 | Form 4 |
| 2026-09-24 | Otero Jose Manuel | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 54,750 | — | $0 | Form 4 |
| 2026-09-24 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 145,500 | — | $0 | Form 4 |
| 2026-09-24 | Bhalla Narinder Pal | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 54,750 | — | $0 | Form 4 |
| 2026-09-14 | Otero Jose Manuel | Officer (Chief Operating Officer) | Grant / award / vesting | 2,110 | $2.64 | $5.6K | Form 4 |
| 2026-09-14 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 2,306 | $2.64 | $6.1K | Form 4 |
| 2026-09-14 | Bhalla Narinder Pal | Officer (Chief Medical Officer) | Grant / award / vesting | 2,714 | $3.58 | $9.7K | Form 4 |
| 2026-08-18 | Otero Jose Manuel | Officer (Chief Operating Officer) | Open-market sale | 1,304 | $4.96 | $6.5K | Form 4 |
| 2026-08-18 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Open-market sale | 3,345 | $4.95 | $16.6K | Form 4 |
| 2026-08-18 | Tamayo Louis Edward | Officer (Chief Financial Officer) | Open-market sale | 4,117 | $4.91 | $20.2K | Form 4 |
| 2026-07-01 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Open-market sale | 25,947 | $4.48 | $116.2K | Form 4 |
| 2026-07-01 | Bhalla Narinder Pal | Officer (Chief Medical Officer) | Open-market sale | 22,306 | $4.42 | $98.6K | Form 4 |
| 2026-07-01 | Otero Jose Manuel | Officer (Chief Operating Officer) | Open-market sale | 4,666 | $4.48 | $20.9K | Form 4 |
| 2026-07-01 | Tamayo Louis Edward | Officer (Chief Financial Officer) | Open-market sale | 4,641 | $4.49 | $20.8K | Form 4 |
| 2026-06-29 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 67,000 | — | $0 | Form 4 |
| 2026-06-29 | Bhalla Narinder Pal | Officer (Chief Medical Officer) | Grant / award / vesting | 55,000 | — | $0 | Form 4 |
| 2026-06-29 | Otero Jose Manuel | Officer (Chief Operating Officer) | Grant / award / vesting | 12,060 | — | $0 | Form 4 |
| 2026-06-29 | Tamayo Louis Edward | Officer (Chief Financial Officer) | Grant / award / vesting | 12,000 | — | $0 | Form 4 |
| 2026-06-25 | CHOLMONDELEY PAULA H | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | Van Hauwermeiren Timothy | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | Tanguler Tolga | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | DIAZ REINALDO M | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | COOPERSTONE BRENDA | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | Agger Mette Kirstine | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-25 | Altschuler Steven | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-05-18 | Townsend Richard Nolan | Director, Officer (Chief Executive Officer) | Open-market sale | 3,342 | $5.06 | $16.9K | Form 4 |
| 2026-05-18 | Otero Jose Manuel | Officer (Chief Operating Officer) | Open-market sale | 1,302 | $5.07 | $6.6K | Form 4 |
| 2026-04-28 | Sepp-Lorenzino Laura | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
Ask the chat about LXEO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LEXEO THERAPEUTICS INC (LXEO).
Last updated 2026-09-24 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.